About Caris Life Sciences
Caris Life Sciences is a company based in Irving (United States) founded in 1996. It operates as a AI-as-a-Service, Professional Services, and HealthTech. Caris Life Sciences has raised $1.23 billion across 9 funding rounds from investors including Fidelity Investments, TPG and T. Rowe Price. The company has 1,339 employees as of December 31, 2022. Caris Life Sciences has completed 1 acquisition, including Caris Life Sciences. Caris Life Sciences offers products and services including Caris Assure, MI Profile, and Caris Molecular AI. Caris Life Sciences operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Irving, United States
- Employees 1339 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Caris Life Sciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.23 B (USD)
in 9 rounds
-
Latest Funding Round
$168 M (USD), Series D
Apr 07, 2025
-
Investors
Fidelity Investments
& 19 more
-
Employee Count
1339
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Caris Life Sciences
Caris Life Sciences is a publicly listed company on the NASDAQ with ticker symbol CAI in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Caris Life Sciences
Caris Life Sciences offers a comprehensive portfolio of products and services, including Caris Assure, MI Profile, and Caris Molecular AI.
Blood-based sequencing is used for deep molecular insights.
Tissue profiling is provided for comprehensive molecular blueprints.
AI solutions are applied for cancer classification insights.
People of Caris Life Sciences
Unlock access to complete
Unlock access to complete
Leadership Team
113 people
Software Development Team
75 people
Molecular Team
55 people
Senior Team
31 people
Data Analysis and Operations Team
30 people
Sales and Marketing
25 people
Account Team
22 people
Operations Team
22 people
Unlock access to complete
Funding Insights of Caris Life Sciences
Caris Life Sciences has successfully raised a total of $1.23B across 9 strategic funding rounds. The most recent funding activity was a Series D round of $168 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Caris Life Sciences
Caris Life Sciences has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, TPG and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Caris Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Caris Life Sciences
Caris Life Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Caris Life Sciences.
Investment portfolio details for Caris Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oncology-focused CRO and SMO services are provided for clinical development.
|
Locked | Locked | 1987 | Locked |
Complete acquisition details for Caris Life Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Caris Life Sciences
Detailed financials for Caris Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Caris Life Sciences Comparisons
Peer comparison for Caris Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Caris Life Sciences
Caris Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Caris Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Caris Life Sciences
Complete news archive for Caris Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caris Life Sciences
Caris Life Sciences was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Caris Life Sciences is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
Caris Life Sciences is a funded company, having raised a total of $1.23B across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Caris Life Sciences is 1,339.
Caris Life Sciences is engaged in revolutionizing cancer care through precision medicine. The company is recognized for developing innovative solutions that analyze biological networks at the molecular level. Services are provided across the care continuum, including disease detection, therapy selection, and treatment monitoring. Advanced technologies in molecular profiling and AI are utilized to inform personalized treatment decisions. The healthcare sector is primarily served, with a focus on oncology. Comprehensive databases combining genomic, transcriptomic, and proteomic data with clinical outcomes are maintained. Solutions are offered to patients, physicians, and biopharma partners to improve patient outcomes globally.
Caris Life Sciences's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Caris Life Sciences offers Caris Assure, MI Profile, and Caris Molecular AI.
Yes, Caris Life Sciences is publicly traded on NASDAQ under the ticker symbol CAI.
Caris Life Sciences has made 1 acquisition, including Caris Life Sciences.
Caris Life Sciences has 20 investors. Key investors include Fidelity Investments, TPG, T. Rowe Price, Orbimed, and CPP Investments.
The ticker symbol of Caris Life Sciences is CAI on NASDAQ.
The valuation of Caris Life Sciences is $7.83B as of May 2021.